The adenomatous polyposis coli (APC) tumor suppressor protein is inactivated by mutations in the majority of colorectal cancers. A recent study has revealed that alterations in the APC signaling pathway can result in the transcriptional activation of the c-MYC gene.
Now that more than 50 different oncogenes and more than 20 different tumor suppressor genes have been identified, it has become increasingly apparent that cancer-associated mutations target conserved signaling pathways. For instance, the function of the retinoblastoma (pRb) tumor suppressor protein is regulated by cyclin D1, cyclindependent kinase 4 (Cdk4) and the p16 tumor suppressor protein (which inhibits Cdk4 activity). Virtually all cancers have inactivating mutations in the pRb or p16 tumor suppressor genes or activating mutations (for example, gene amplification) affecting cyclin D1 or Cdk4 [1] .
Although recurrent clonal mutations have been ascribed a critical and causal role in cancer development, gene expression changes in cancer cells themselves have been viewed more suspiciously. In the absence of a genetic lesion that accounts for a change in gene expression, it is not clear whether the altered expression of a particular gene is a cause or effect of the cancer phenotype, even for those genes that are known to function as oncogenes or tumor suppressor genes when mutated. If, however, an alteration in gene expression can be definitively linked to a specific mutation in a pathway involving an oncogene or a tumor suppressor gene, then the argument that the altered expression has a causal role in cancer development becomes more compelling.
Bearing these points in mind, one can readily appreciate the interest stimulated by the recent work from He et al. [2] describing a relationship between the adenomatous polyposis coli (APC) tumor suppressor gene pathway and c-MYC. The c-MYC gene is affected by chromosomal rearrangements and gene amplifications in certain cancers, but is perhaps most frequently mutated in Burkitt's lymphoma and small cell lung carcinoma [3] . In most common types of cancer, however, including colorectal cancer, c-MYC gene rearrangements and amplifications are rare or absent. Although earlier studies documented that c-MYC expression was increased in most colorectal cancers [4] , the basis for altered c-MYC expression in colorectal cancer and the biological significance of this altered expression has remained enigmatic. He et al. [2] now provide strong evidence that increased c-MYC expression in colorectal cancer is likely to be a direct consequence of mutations affecting the APC tumor suppressor pathway.
Before considering the findings of He et al. [2] further, it is useful to review prior insights into APC function. Germ-line, inactivating mutations in one APC allele are responsible for familial adenomatous polyposis, and somatic APC mutations are seen in roughly 70% of colorectal adenomas and carcinomas but are rare in other cancers [5] . APC encodes a large protein of about 300 kDa, and some data suggest that APC might regulate cell growth in the colonic crypt via effects on shedding and apoptosis as cells reach the top of the crypt [5] . Consistent with this view, inactivation of APC leads to marked cellular atypia and disordered growth -termed dysplasia -in colonic epithelial cells (Figure 1 ), and restoration of APC protein expression in colorectal cancer cells that lack endogenous APC promotes apoptosis [6] . As well as binding to microtubules, the APC protein binds to various proteins, including β-catenin, γ-catenin, glycogen synthase kinase 3β (GSK3β), the microtubulebinding protein EB1, and the cell polarity protein hDLG [5] . The significance of any of these interactions was not evident until recently, however, when data established that a critical function of APC is the regulation of β-catenin protein stability.
The β-catenin protein was initially identified because of its role in linking the cytoplasmic domain of the cell-adhesion protein E-cadherin to the cortical actin cytoskeleton [7] . In addition to its role in E-cadherin-mediated cell-cell adhesion, β-catenin also functions in the Wnt/Wingless signaling pathway, which is involved in modulating cell fate, proliferation and behavior during development [7] ( Figure 2 ). In brief, binding of Wnt to the Frizzled transmembrane receptor is believed to activate the Disheveled protein, which, in turn, inhibits the function of GSK3β. When bound to APC and axin, GSK3β appears to phosphorylate specific serine and threonine residues in the amino terminus of β-catenin. Phosphorylated but not unphosphorylated β-catenin is rapidly degraded by the ubiquitin-proteasome pathway. Wnt activation therefore promotes the accumulation of unphosphorylated β-catenin in the cell. Following its accumulation, β-catenin translocates to the nucleus where it binds to the T-cell factor (Tcf) or lymphoid enhancer factor (Lef) transcription factors and acts as a transcriptional co-activator, leading to increased expression of Tcf/Lef-regulated target genes.
Although inactivating mutations in APC are present in the majority of colorectal cancers, mutations of the amino-terminal presumptive GSK3β phosphorylation sites in β-catenin have also been found in a minority of colorectal cancers [8] . In both of these cases -that is, whether APC is inactivated or β-catenin is non-phosphorylatable -β-catenin is no longer appropriately regulated (Figure 2 ).
The protein accumulates in the cell, binds to Tcf/Lef transcription factors, such as Tcf-4, and activates gene expression. Therefore, one of the major outstanding issues with respect to the APC pathway is the identity of the Tcf-regulated genes that are activated as a result of mutations in APC or β-catenin.
He et al. [2] sought to identify Tcf-regulated genes using a colorectal cancer cell line in which the endogenous APC was inactive and an exogenous APC gene could be rapidly induced. To monitor changes in gene expression following induction of APC, the serial analysis of gene expression (SAGE) method was used. In brief, the SAGE technique is a sequence-based approach that allows an unbiased assessment of changes in RNA transcript abundance between different RNA populations. Among the changes observed, He et al. found that c-MYC expression was strongly suppressed by APC induction. Further investigation revealed that the critical elements in the c-MYC promoter that were responsible for APC-mediated suppression included Tcf-binding sites. Wild-type APC suppressed the activity of heterologous reporter genes whose expression was driven by the Tcf regulatory elements from the c-MYC promoter. Furthermore, expression of the mutated form of β-catenin led to high levels of activation of reporter gene expression from these constructs. The studies of He et al. [2] thus provide strong evidence that the APC protein may regulate c-MYC expression through its effects on β-catenin and Tcf-4. Intriguingly, a role for APC in the regulation of c-MYC gene expression was first suggested a number of years ago on the basis of results from two independent lines of investigation. The first study revealed that increased c-MYC expression was associated with loss of the chromosome 5q region where the APC gene resides [9] . The second study observed that introduction of a normal copy of chromosome 5q into colorectal cancer cells suppressed c-MYC expression [10] .
What then is the contribution of c-MYC overexpression to the phenotype of colorectal cancer cells? Since the identification of c-MYC as a cellular homologue of the retroviral v-myc oncogene 20 years ago, significant insights into its function have been gained. The primary product of the c-MYC gene is a 64 kDa polypeptide that functions as a transcription factor when heterodimerized with the Max protein [3] . The regulation of c-Myc target genes is complex, because other proteins, such as the Mad proteins, compete with c-Myc for binding to Max. In contrast to the action of Myc-Max heterodimers, Mad-Max heterodimers repress transcription of target genes.
Despite this complexity, many intriguing candidate target genes of c-Myc have been identified, including those encoding cell-cycle regulators, such as cdc25A, cyclin A, Figure 1 Transverse section of a microscopic adenoma from a patient with familial adenomatous polyposis. Roughly five adenomatous glands are seen at the top of the figure (arrow), above a collection of normal colonic glands. The adenomatous glands can be readily distinguished from the normal glands, because they manifest dysplastic changes. Characteristic features of dysplastic epithelium include increased cellularity and abnormal cellular morphology, with hyperchromatic and spindle-shaped nuclei, nuclear stratification, and loss of nuclear polarity. The patient from which this sample was taken carries one mutant and one normal (wild-type) APC allele in each cell of his body. Inactivation of the remaining wild-type APC allele is believed to be critical in initiating growth of the dysplastic (adenomatous) glands.
and cyclin E, as well as proteins associated with DNA metabolism, such as carbamoyl phosphate synthase, ornithine decarboxylase, dihydrofolate reductase, thymidine kinase, and the reverse transcriptase component of telomerase [3] . Other potential c-Myc target genes include several that encode proteins involved in cellular metabolism, such as the translational regulatory factors eIF-2α and eIF-4E, the amino acid transporter ECA39, and lactate dehydrogenase A which participates in anaerobic glycolysis [3] . Overall, the data imply that increased expression of the c-Myc protein in colorectal cancer may directly disrupt cell-cycle control and promote entry into the S phase of the cell cycle. As He et al. [2] noted, c-MYC activation appears to have similar effects on cell-cycle control to those caused by mutations in the pRb-p16 pathway [11] , and mutations in the pRb-p16 pathway are extremely infrequent in colorectal cancer [1] . Because of its ability to activate genes with important roles in cell metabolism and energy balance, c-MYC may also facilitate cell proliferation in conditions that might otherwise inhibit growth or promote death by apoptosis.
In summary, we now have intriguing insights into the basis for increased c-MYC expression in colorectal cancer, and c-MYC's role is no longer simply one of guilt by association. Further studies will be required to determine which c-Myc target genes are activated in colorectal cancer, although some potential candidates, such as prothymosin α, have previously been found to be overexpressed in colorectal cancers [12] . Moreover, c-MYC is likely to be only one of a number of genes activated as a result of Tcf deregulation. Based on the many histopathological changes seen in early stage colonic lesions following APC inactivation (Figure 1) , it seems reasonable to predict that other genes with roles in cell-cell interaction and cell proliferation will be identified as critical targets of the APC-β-catenin-Tcf-4 pathway. An optimistic view is that focused and well-controlled studies using the powerful new technologies for monitoring gene expression changes will provide us with further insights into oncogene and tumor suppressor gene networks as well as into the biological bases for the development of colorectal and other cancers. 
